| Literature DB >> 35800218 |
Sangavi Pandi1, Langeswaran Kulanthaivel1, Gowtham Kumar Subbaraj2, Sangeetha Rajaram3, Senthilkumar Subramanian4.
Abstract
Cyclooxygenase-2 (COX-2) is a key enzyme involved in overexpression in several human cancerous diseases including breast cancer. By performing efficient virtual screening in a series of active molecules or compounds from the Maybridge, NCI (National Cancer Institute), and Enamine databases, potential identification of COX-2 inhibitors could lead to new prognostic strategies in the treatment of breast cancer. Based on a 50% structural similitude, compounds were chosen as the inductive model of COX-2 inhibitions from these databases. Selected compounds were filtered and tested with Lipinski's rule of five followed by absorption, distribution, metabolism, and excretion (ADME) properties. Subsequently, molecular docking was performed to achieve accuracy in screening and also to find an interactive mechanism between hit compounds with their respective binding sites. Simultaneously, molecular simulations of top-scored compounds were selected and coded such as Maybridge_55417, NCI_30552, and Enamine_62410. Chosen compounds were analyzed and interpreted with COX-2 affinity. Results endorsed that hydrophobic affinity and optimum hydrogen bonds were the forces driven in the interactive mechanism of in silico hits compounds with COX-2 and can be used as efficient alternative therapeutic agents targeting deleterious breast cancer. With these in silico findings, compounds identified may prevent the action of the COX-2 enzyme and thereby diminish the incidence of breast cancer.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35800218 PMCID: PMC9256436 DOI: 10.1155/2022/3338549
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Figure 1The workflow.
Illustrates the selected potent compounds and their Glide XP, fitness scores, and their interaction residues with COX-2 pattern.
| S. no | Compound ID | Glide XP score (kcal/Mol) | Glide energy (kcal/Mol) | Interacting residue | Fit score |
|---|---|---|---|---|---|
| 1 | Maybridge_55417 | -10.503 | -59.842 | H_207 (HB) F_210, T_212, N_382 (PI-PI) | 1.239 |
| 2 | NCI_30552 | -8.859 | -52.268 | H_207,H_386, HIE_388 (HB)W_387, N_382 (PI-PI) | 1.564 |
| 3 | Enamine_62410 | -8.584 | -45.301 | H_207(HB) Q_289, T_212, Y_385, N_382 (PI-PI) | 1.673 |
Figure 2Protein-ligand interactions of selected compounds of the Maybridge, NCI, and Enamine databases with best binding poses and interactions of compounds in the active site of protein.
Showing binding free energy scores and HOMO, LUMO, and MESP of hit potential compounds.
| S.no | Compound ID | Δ | HOMO (eV) | LUMO (eV) | Solv. energy (kcal/Mol) |
|---|---|---|---|---|---|
| 1. | Maybridge_55417 | -59.958 | -0.23966 | -0.04770 | -18.26 |
| 2. | NCI_30552 | -44.559 | -0.21548 | -0.06670 | -14.51 |
| 3. | Enamine_62410 | -52.341 | -0.13743 | -0.03969 | -8.88 |
Figure 3HOMO of lead potential compounds.
Figure 4LUMO of lead potential compounds.
Figure 5MESP of lead potential compounds.
Showing ADME properties of identified compounds using the Qikprop module.
| S.no | Compound ID | MW | Donor HB | Accept HB | %human oral absorption | QPlogPo/w | QPPCaco | QPPMDCK | Rule of five |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Maybridge_55417 | 446.31 | 1.000 | 5.500 | 100 | 4.723 | 693.684 | 7564.41 | 0 |
| 2. | NCI_30552 | 410.42 | 2.000 | 4.500 | 100 | 4.852 | 584.333 | 276.782 | 0 |
| 3. | Enamine_62410 | 263.21 | 3.000 | 5.250 | 100 | 1.027 | 317.25 | 3089.67 | 0 |
Figure 6Time dependence of the radius of gyration (Rg) graph of Maybridge_55417 NCI_30552 and Enamine_62410 complexes. Red color for Maybridge_55417 compound, black color indicates NCI_30552 compound, and green color indicates Enamine_62410 compound at different time scales (20 to 50 ns).
Figure 7Hydrogen bond interaction between protein-ligand complexes.